LOMONOX
Overview:
Lomonox contains Enoxaparin Sodium, a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat deep vein thrombosis (DVT), pulmonary embolism (PE), and thromboembolic complications in high-risk patients. It provides effective clot prevention with a predictable anticoagulant response, making it a preferred choice in both hospital and outpatient settings.
- Class
- Dosage
- Indications
- Mechanism of action
Anticoagulant
DVT/PE Prevention (Prophylaxis):
General Surgery: 40 mg subcutaneously (SC).
Orthopedic Surgery: 30 mg SC every 12 hours or 40 mg.
DVT/PE Treatment: 1 mg/kg SC every 12 hours or 1.5 mg/kg SC.
Acute Coronary Syndrome (ACS): 1 mg/kg SC every 12 hours along with aspirin.
Administered subcutaneously; not for intramuscular injection.
- Prevention & treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE)
- Prevention of clot formation in surgical & bedridden patients
- Management of unstable angina & non-ST elevation myocardial infarction (NSTEMI)
- Prevention of thromboembolic complications in dialysis patients
Lomonox (Enoxaparin) enhances antithrombin III (ATIII) activity, leading to inhibition of Factor Xa and Factor IIa (thrombin). This prevents clot formation while maintaining blood flow, reducing the risk of thrombosis without significant platelet inhibition. Due to its high anti-Xa to anti-IIa ratio, Enoxaparin offers enhanced safety, fewer bleeding risks, and more predictable anticoagulation compared to unfractionated heparin (UFH).
